

### INTERVIEW SUMMARY

On December 3, 2008, the undersigned attorney and Examiner Kim discussed the rejections of the claims under 35 U.S.C. § 102 over Pene et al. and Hata et al. Applicant's attorney pointed that pages 6-8 of the specification explain how SC-02MFP may be produced from RPMI8226, and how SC-01MFP may be produced from KMS-12BM. The Examiner agreed that those sections the specification will overcome the rejections over Pene et al. and Hata et al., and also asked the Applicant's attorney to submit written remarks for confirmation.

### REMARKS

Claims 20 and 21 are currently pending. Claims 8-18 were previously withdrawn.

#### *Objections to the Specification*

The Office Action objects to the specification in that it makes certain references to cell strains SC. 01MFP and SC. 02MFP and KMS.12BM. Those references are clerical errors due to a conversion of fonts. As the Office Action requests, correction is made in the attached Substitute Specification. Accordingly, Applicant requests withdrawal of this objection.

#### *Claim Objections*

Claims 20 and 21 recite SC-02MFP and SC-01MFP, respectively. As noted above, the Specification has been corrected and is now consistent with the claims. Accordingly, Applicant requests withdrawal of this objection.

#### *Claim Rejections*

The Office Action rejected Claim 20 over Pene et al. The Office Action states that Pene et al. teaches the cell "RMP18226". It also asserts that SC-02MFP (as recited in claim 20) must be the same as RMP18226 because Applicant's specification fails to disclose any method of preparing SC-02MFP. Applicant respectfully disagrees. Pages 6-8 of the specification (paragraphs 0026-0033) specifically describe how SC-02MFP may be produced from

RMP18226. The method may include, for example, the selection of cell strains within a certain weight range, and inducing mutation in a medium in which nitrosoguanidine has been added. Accordingly, Applicant requests withdrawal of this rejection.

The Office Action rejected Claim 21 over Hata et al. The Office Action states that Hata et al. teaches the cell line “KMS12BM”. It also asserts that SC-01MFP (as recited in claim 21) must be the same as KMS12BM because Applicant’s specification fails to disclose any method of preparing SC-01MFP. Applicants respectfully disagree. Pages 6-8 of the specification (paragraphs 0026-0033) specifically describe how SC-01MFP may be produced from KMS-12BM. The method may include, for example, the selection of cell strains within a certain weight range, and inducing mutation in a medium in which nitrosoguanidine has been added. Accordingly, Applicant requests withdrawal of this rejection.


CONCLUSION

Applicants have timely filed this response. In the event that an additional fee is required for this response, the Commissioner is hereby authorized to charge such fees to Deposit Account No. 50-0436.

Applicants believe that this application is in condition for allowance. However, should the Examiner have any questions or comments, or need any additional information from Applicant's attorney, please contact the undersigned attorney at your convenience.

A *Substitute Specification* follows.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'JMS', with a long horizontal flourish extending to the right.

James M. Singer  
Registration No. 45,111

PEPPER HAMILTON LLP  
One Mellon Center, 50<sup>th</sup> Floor  
500 Grant Street  
Pittsburgh, PA 15219  
Phone: (412) 454-5000  
Fax: (412) 281-0717  
Date: December 3, 2008